Chemical Compound
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine; 4-(3-Chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; Gefitinib; Gefonib; Iressa; ZD 1839; ZD1839
CAS Registry Number
184475-35-2
Primary record
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine; 4-(3-Chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; Gefitinib; Gefonib; Iressa; ZD 1839; ZD1839
- 库存
- 2,172 克
- 纯度
- 99.2 %
- CAS
- 184475-35-2
化合物标识与属性
- CAS
- 184475-35-2
- PubChem CID
- 123631
- SMILES
- COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
- Canonical SMILES
- COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1
名称与同义词
- Gefitinib
- Iressa
- 184475-35-2
- Irressat
- gefitinibum
- Tarceva
- gefitinib (zd1839)
- ZD1839
- Gefitinib [USAN]
- Gefitini
- Gefitinib; Iressa
- Gefitinib;
- Irressat;
- Iressa/Gefitinib
- Gefitinib (GMP)
- Gefitinib RS
- Iressa(TM)
- Gefitinib CRS
- Gefitinib-d3
- Iressa;
- Gefitini; Iressa
- Iressa (TN)
- C22H24ClFN4O3
- GefitinibZD1839
- Gefitinib - Iressa
- ZD-1839
- IRRESSA
- ZD 1839
- Gefitinib (Standard)
- Iressa (AstraZeneca)
- nchembio866-comp14
- Iressa-1839
- Kinome_3321
- Kinome_3322
- CHEMBL939
- GEFITINIB [INN]
- GEFITINIB [JAN]
- RefChem:58462
- GEFITINIB [MI]
- CCRIS 9011
- GEFITINIB [VANDF]
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
- S65743JHBS
- UNII-S65743JHBS
- DTXSID8041034
- Gefitinib [USAN:INN:BAN]
- MFCD04307832
- D09XZB
- Gefitinib (ZD1839)?
- GEFITINIB [MART.]
- Iressa|||ZD 1839
- AC1L3X0A
- GEFITINIB [WHO-DD]
- SCHEMBL7866
- XGALLCVXEZPNRQ-UHFFFAOYSA-N
- Gefitinib,Iressa, ZD1839
- Gefitinib,ZD-1839,Iressa
- Gefitinib/ZD-1839,Iressa
- DTXCID6021034
- GEFITINIB [EMA EPAR]
- KBioSS_002241
- cc-596
- CHEBI:49668
- Gefitinib (JAN/USAN/INN)
- MLS003899193
- NSC-759856
- Gefitinib - Bio-X trade mark
- Gefitinib, Iressa, ZD1839
- BDBM5447
- cid_123631
- EBD446
- GTPL4941
- orb1309499
- SCHEMBL4535121
- SCHEMBL4535128
- SCHEMBL4535134
- Gefitinib (JP18/USAN/INN)
- GEFITINIB [ORANGE BOOK]
- Tyrosine Kinase Inhibitor - Ns
- ZD-1839, Iressa, Gefitinib
- GEFITINIB [EP MONOGRAPH]
- Gefitinib, >=98% (HPLC)
- SCHEMBL29351046
- SCHEMBL29351336
- CTK7A0364
- Gefitinib, 99% - 1MG 1mg
- AOB6917
- L01XE02
- QCR-105
- SYN1042
- NSC715055
- BCPP000221
- GLXC-05820
- HMS2089B19
- HMS3244M21
- HMS3244M22
- HMS3244N21
- HMS3295A21
- HMS3413H08
- HMS3654A07
- HMS3677H08
- HMS3714A05
- HMS3748E17
- HMS5079C05
- Pharmakon1600-01502274
- AMX10169
- BCP01365
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
- YWB97640
- C22-H24-Cl-F-N4-O3
- Tox21_111683
- ABP000855
- BBF-04570
- CG0031
- CID123631
- EBC-07543
- FC0028
- Gefitinib for system suitability CRS
- HY-50895G
- HY-50895R
- MSK159193
- NCGC00159455-02
- NSC759856
- NSC800105
- RS0033
- s1025
- STK621310
- ZINC19632614
- AKOS000280752
- Tox21_111683_1
- AB20814
- AC-1556
- ACN-032362
- AN-5192
- BCP9000718
- CCG-220642
- CID:123631
- CS-0124
- DB00317
- FG10816
- KS-1204
- NSC 759856
- NSC-715055
- NSC-800105
- SDCCGSBI-0634411.P005
- KS-00000E11
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
- NCGC00159455-03
- NCGC00159455-04
- NCGC00159455-05
- NCGC00159455-06
- NCGC00159455-08
- NCGC00159455-09
- NCGC00159455-14
- 4CA-0562
- AJ-74091
- AK-72948
- BC215794
- BCB03_000781
- BG164498
- BR-72948
- CJ-16232
- EN002708
- H018
- HY-50895
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
- SC-18023
- SMR002204119
- SY002154
- 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
- SID:376229605
- AB0000095
- LS-139916
- ST2413546
- A8219
- AM20090619
- CAS-184475-35-2
- CS-0622782
- FT-0602325
- G0546
- NS00006312
- SW199108-4
- EC-000.2409
- J1.437.124I
- A10422
- CU-00000000396-1
- D01977
- EN300-123024
- G-4408
- J10250
- K00240
- N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
- S-2176
- 15215-EP2269994A1
- 15215-EP2272827A1
- 15215-EP2272832A1
- 15215-EP2275413A1
- 15215-EP2277865A1
- 15215-EP2280006A1
- 15215-EP2281813A1
- 15215-EP2281815A1
- 15215-EP2287156A1
- 15215-EP2292234A1
- 15215-EP2292615A1
- 15215-EP2298768A1
- 15215-EP2298778A1
- 15215-EP2301533A1
- 15215-EP2301933A1
- 15215-EP2305640A2
- 15215-EP2305671A1
- 15215-EP2311807A1
- 15215-EP2311827A1
- 15215-EP2311840A1
- 15215-EP2316832A1
- 15215-EP2316833A1
- 32333-EP2281815A1
- 32333-EP2292615A1
- 32333-EP2301933A1
- 32333-EP2305640A2
- 32333-EP2305671A1
- 32333-EP2311827A1
- AB01273954-01
- AB01273954-02
- AB01273954-03
- AB01273954_04
- 475G352
- A812870
- C419708
- Q417824
- SR-00000000262
- I01-1227
- SR-00000000262-2
- SR-00000000262-3
- BRD-K64052750-001-16-7
- BRD-K64052750-001-17-5
- BRD-K64052750-001-22-5
- BRD-K64052750-001-23-3
- Gefitinib, EuropePharmacopoeia (EP) Reference Standard
- D000077156
- Z1546610485
- 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
- 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-
- N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
- 3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline
- 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline
- 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-
- 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
- 4-(3-chloro-4-fluoroanilino)-6-(3-morpholinopropoxy)-7-methoxyquinazoline
- 857091-32-8
- IRE
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(2,2,3,3,5,5,6,6-octadeuteriomorpholin-4-yl)propoxy]quinazolin-4-amine
- 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline
- 4-(3-CHLORO-4-FLUOROANILINO)-7-METHOXY-6-(3-MORPHOLINOPROPOXY)QUINAZOLINE
- 4-Quinazolinamine,N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
- Gefitinib for system suitability, EuropePharmacopoeia (EP) Reference Standard
- N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4 -ylpropoxy)quinazolin-4-amine
- N-(3-Chloro-4-fluorophenyl)-6-(3-morpholinopropoxy)-7-methoxy-4-quinazolinamine
- N-(3-Chloro-4-fluorophenyl)-6-(3-morpholinopropoxy)-7-methoxyquinazoline-4-amine
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholin) propoxy)-4-quinazolinamine
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(morpholin-4-yl)propoxy)quinazolin-4-amine
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)-4-quinazolinamine
- (3-CHLORO-4-FLUORO-PHENYL)-[7-METHOXY-6-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-4-YL]-AMINE
- 1173976-40-3
- 643-034-7
- N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; hydrochloride
- N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; (3-Chloro-4-fluorophenyl)[7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-yl]amine; 4-(3-Chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxy]quinazoline; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; Gefitinib; Gefonib; Iressa; ZD 1839; ZD1839